Meeting
2019 ASCO Annual Meeting
Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase III study (PERSEUS).
Authors
Pieter Sonneveld
Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
Pieter Sonneveld , Annemiek Broijl , Francesca Gay , Mario Boccadoro , Hermann Einsele , Joan Blade , Meletios A. Dimopoulos , Michel Delforge , Andrew Spencer , Roman Hajek , Fredrik Schjesvold , Sarah Lonergan , Elena Smith , Robin L. Carson , Wendy Crist , Wendy S. Garvin , Jessica Vermeulen , Philippe Moreau
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies—Plasma Cell Dyscrasia
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT03710603
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS8055)
DOI
10.1200/JCO.2019.37.15_suppl.TPS8055
Abstract #
TPS8055
Poster Bd #
379b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab + daratumumab + lenalidomide (EDR) versus daratumumab + lenalidomide + dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM).
First Author: Sebastian Grosicki
Poster
2019 ASCO Annual Meeting
Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with newly diagnosed multiple myeloma (NDMM) for whom transplant is not planned as initial therapy: A multicenter, randomized, phase III study (CEPHEUS).
First Author: Sonja Zweegman
Poster
2018 ASCO Annual Meeting
Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): A multicenter, randomized, phase 3 study (APOLLO).
First Author: Pieter Sonneveld
Poster
2023 ASCO Annual Meeting
A phase 1 study of belantamab mafodotin in combination with standard of care in newly diagnosed multiple myeloma: An interim analysis of DREAMM-9.
First Author: Saad Zafar Usmani